ofloxacin has been researched along with Cystic Fibrosis in 27 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics and tolerability of nebulized MP-376 (levofloxacin inhalation solution [Aeroquin]) were determined in cystic fibrosis (CF) subjects." | 9.15 | Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. ( Dudley, MN; Flume, PA; Geller, DE; Griffith, DC; Loutit, JS; Morgan, E; White, D, 2011) |
| "Levofloxacin is used in adult patients with cystic fibrosis but its pharmacokinetics is not well characterized in this population." | 9.12 | Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. ( Allen, SE; Amsden, GW; Pai, MP, 2006) |
| "The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients." | 9.06 | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987) |
| "The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection." | 9.06 | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987) |
| "Levofloxacin is a fluoroquinolone with extensive renal elimination and enhanced penetration into lungs and Pseudomonas aeruginosa (PA) biofilms." | 6.73 | Levofloxacin pharmacokinetics in adult cystic fibrosis. ( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 5.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| "The pharmacokinetics and tolerability of nebulized MP-376 (levofloxacin inhalation solution [Aeroquin]) were determined in cystic fibrosis (CF) subjects." | 5.15 | Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. ( Dudley, MN; Flume, PA; Geller, DE; Griffith, DC; Loutit, JS; Morgan, E; White, D, 2011) |
| "Levofloxacin is used in adult patients with cystic fibrosis but its pharmacokinetics is not well characterized in this population." | 5.12 | Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. ( Allen, SE; Amsden, GW; Pai, MP, 2006) |
| "The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients." | 5.06 | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987) |
| "The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection." | 5.06 | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987) |
| "Levofloxacin is a fluoroquinolone with extensive renal elimination and enhanced penetration into lungs and Pseudomonas aeruginosa (PA) biofilms." | 2.73 | Levofloxacin pharmacokinetics in adult cystic fibrosis. ( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007) |
| "The treatment with ofloxacin in accordance with the above scheme resulted in a rapid improvement of the patient state: the intoxication lowered, the expectoration and the sputum viscosity decreased, the body temperature normalized by the 5th day." | 2.68 | [An attempt to use ofloxacin in patients with mucoviscidosis]. ( Apul'tsina, ID; Chuchalin, AG; GUgutsidze, EN; Kuchkina, NV; Samsonova, MV; Sokolov, AS, 1996) |
| " Older literature supports an oral dosing regimen of 40 mg/kg/day divided every 12 hr, up to 2 g/day, and intravenous (IV) ciprofloxacin 30 mg/kg/day divided every 8 hr, maximum 1." | 2.49 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013) |
| "Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml." | 1.36 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (29.63) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| King, P | 2 |
| Lomovskaya, O | 2 |
| Griffith, DC | 3 |
| Burns, JL | 1 |
| Dudley, MN | 3 |
| Citron, DM | 1 |
| Geller, DE | 2 |
| Flume, PA | 2 |
| Morgan, E | 1 |
| White, D | 1 |
| Loutit, JS | 2 |
| Staab, D | 1 |
| Fischer, R | 1 |
| Conrad, DJ | 1 |
| Fernández-Olmos, A | 1 |
| García-Castillo, M | 1 |
| Maiz, L | 1 |
| Lamas, A | 1 |
| Baquero, F | 1 |
| Cantón, R | 1 |
| Stockmann, C | 1 |
| Sherwin, CM | 1 |
| Zobell, JT | 1 |
| Young, DC | 1 |
| Waters, CD | 1 |
| Spigarelli, MG | 1 |
| Ampofo, K | 1 |
| Postnikov, SS | 2 |
| Semykin, SIu | 1 |
| Nazhimov, VP | 1 |
| Novichkova, GA | 1 |
| Golini, G | 1 |
| Favari, F | 1 |
| Marchetti, F | 1 |
| Fontana, R | 1 |
| McKnight, AJ | 1 |
| Shaw, A | 1 |
| Goldsmith, CE | 1 |
| Clarke, L | 1 |
| Millar, BC | 1 |
| McCaughan, J | 1 |
| Elborn, JS | 1 |
| Reid, A | 1 |
| Moore, JE | 1 |
| Roveta, S | 1 |
| Schito, AM | 1 |
| Marchese, A | 1 |
| Schito, GC | 1 |
| Pai, MP | 1 |
| Allen, SE | 1 |
| Amsden, GW | 1 |
| Lee, CKK | 1 |
| Boyle, MP | 1 |
| Diener-West, M | 1 |
| Brass-Ernst, L | 1 |
| Noschese, M | 1 |
| Zeitlin, PL | 1 |
| Høiby, N | 3 |
| Pedersen, SS | 4 |
| Jensen, T | 4 |
| Valerius, NH | 1 |
| Koch, C | 3 |
| Upton, C | 1 |
| Chuchalin, AG | 1 |
| Sokolov, AS | 1 |
| Apul'tsina, ID | 1 |
| GUgutsidze, EN | 1 |
| Kuchkina, NV | 1 |
| Samsonova, MV | 1 |
| Gillespie, T | 1 |
| Masterton, RG | 1 |
| Romano, L | 1 |
| Girosi, D | 1 |
| Spallone, E | 1 |
| Parisi, F | 1 |
| Minicucci, L | 1 |
| Romano, C | 1 |
| Croize, J | 1 |
| Gout, JP | 1 |
| Robert, J | 1 |
| Le Noc, P | 1 |
| Pertuiset, E | 1 |
| Lenoir, G | 1 |
| Jehanne, M | 1 |
| Douchain, F | 1 |
| Guillot, M | 1 |
| Menkès, CJ | 1 |
| Kurz, CC | 1 |
| Marget, W | 1 |
| Harms, K | 1 |
| Bertele, RM | 1 |
| Nielsen, B | 1 |
| Nielsen, H | 1 |
| Hvidberg, EF | 1 |
| Nielsen, CH | 1 |
| Meyer, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients[NCT00677365] | Phase 2 | 151 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in the predicted percent of air the patient could exhale in one second (NCT00677365)
Timeframe: from baseline to the end of the treatment 28-day treatment period (28 days)
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | -2.39 |
| MP-376 120 mg QD | 1.96 |
| MP-376 240 mg QD | 3.10 |
| MP-376 240 mg BID | 8.55 |
Patients were required to cough deeply and then spit sputum into a sterile container. The bacteria contained in the sputum sample was incubated in a laboratory and the number of P. aeruginosa colony forming units per gram of sputum (CFU/g) was determined. The difference in CFUs/g were then compared from baseline to the conclusion of the 28 day treatment period (NCT00677365)
Timeframe: from baseline to end of treatment (28 days)
| Intervention | log10 CFU/g sputum (Least Squares Mean) |
|---|---|
| Placebo | 0.23 |
| MP-376 120 mg QD | -0.31 |
| MP-376 240 mg QD | -0.31 |
| MP-376 240 mg BID | -0.73 |
Change in the score from 0 to 100 that a patient reports for their respiratory symptoms in the CFQ-R. An increase in score illustrates an improvement in symptoms. An increase of 4 or more is considered clinically significant (NCT00677365)
Timeframe: from baseline to the end of the 28-day treatment period (28 days)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.44 |
| MP-376 120 mg QD | 2.00 |
| MP-376 240 mg QD | 0.31 |
| MP-376 240 mg BID | 4.06 |
Percent change in the amount of air the patient could exhale in 1 second (NCT00677365)
Timeframe: from baseline to end of the 28-day treatment period (28 days)
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.36 |
| MP-376 120 mg QD | 1.93 |
| MP-376 240 mg QD | 2.56 |
| MP-376 240 mg BID | 6.25 |
Time to administration of other anti-pseudomonal antimicrobials in patients with at least one of the following: decreased exercise tolerance, increased cough, increased sputum/chest congestion, or decreased appetite; 25th percentile data reported (NCT00677365)
Timeframe: from baseline until final study visit (up to 56 days)
| Intervention | days (Mean) |
|---|---|
| Placebo | 31 |
| MP-376 120 mg QD | NA |
| MP-376 240 mg QD | 56 |
| MP-376 240 mg BID | 59 |
All isolates of P. aeruginosa cultures grown from patient sputum samples were evaluated to see whether the minimum concentration of levofloxacin needed to inhibit growth of the bacteria (i.e., minimum inhibitory concentration; MIC) had increased; 2. The MIC50 and MIC90 values were calculated as the 50th percentile value and the 90th percentile value, respectively. Note that percentile values between dilution values were rounded up to the nearest dilution value (NCT00677365)
Timeframe: from baseline until the end of the 28-day treatment period (28 days)
| Intervention | ug/mL (Number) | |||
|---|---|---|---|---|
| Baseline Minimum Inhibitory Concentration (MIC)50 | Day 28 MIC for 50% (MIC50) | Baseline MIC for 90% (MIC90) | Day 28 MIC90 | |
| MP-376 120 mg QD | 4 | 4 | 32 | 16 |
| MP-376 240 mg BID | 4 | 4 | 16 | 32 |
| MP-376 240 mg QD | 4 | 4 | 16 | 16 |
| Placebo | 4 | 4 | 16 | 8 |
3 reviews available for ofloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Dr | 2013 |
Fluoroquinolones in the treatment of cystic fibrosis.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Ofloxacin; Pseudomonas Infections | 1993 |
[Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis].
Topics: Adolescent; Animals; Arthritis; Cartilage, Articular; Child; Cystic Fibrosis; Dogs; Female; Humans; | 1989 |
11 trials available for ofloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Cross-Over S | 2011 |
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationshi | 2011 |
[On fluoroquinolones treatment safety in children (clinical, morphological and catamnesis data)].
Topics: Adolescent; Age Factors; Anemia, Aplastic; Anti-Infective Agents; Body Height; Cartilage; Child; Chi | 2002 |
Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Biological Availability; Calcium Carbonate; Cations; Cross | 2006 |
Levofloxacin pharmacokinetics in adult cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Kidney Function Tests; Le | 2007 |
[An attempt to use ofloxacin in patients with mucoviscidosis].
Topics: Administration, Oral; Anti-Infective Agents; Cystic Fibrosis; Humans; Klebsiella; Microbial Sensitiv | 1996 |
[The use of ofloxacin in cystic fibrosis patients].
Topics: Adolescent; Adult; Analysis of Variance; Chronic Disease; Cystic Fibrosis; Drug Tolerance; Female; H | 1992 |
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as To | 1986 |
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibro | 1987 |
Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Femal | 1987 |
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Drug | 1987 |
13 other studies available for ofloxacin and Cystic Fibrosis
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M | 2010 |
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Aerobiosis; Aerosols; Anaerobiosis; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Levofloxacin; Mi | 2010 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; | 2012 |
Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Burkholderia cepacia; Cystic Fibrosis; Drug Resistance, Bacterial; Haemophilu | 2004 |
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, B | 2005 |
Sleep disturbance in children treated with ofloxacin.
Topics: Child; Cystic Fibrosis; Female; Humans; Male; Ofloxacin; Opportunistic Infections; Pseudomonas Infec | 1994 |
[Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
Topics: Adolescent; Anti-Infective Agents; Arthritis; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosi | 2001 |
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug | 2002 |
[In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Resistanc | 1989 |
Bactericidal effect of polymorphonuclear leukocytes on Pseudomonas aeruginosa pre-incubated in ofloxacin.
Topics: Anti-Bacterial Agents; Blood Bactericidal Activity; Cystic Fibrosis; Humans; Kinetics; Neutrophils; | 1987 |
Ofloxacin in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; | 1987 |